TOPO-1在转移性结直肠癌组织中的表达及与伊立替康化疗的相关性研究

目的　探讨拓扑异构酶1（topoisomerase1，TOPO-1）在转移性结直肠癌组织中的表达，并分析其与伊立替康（CPT-11）化疗疗效的相关性。方法 经病理活检证实为转移性结直肠癌初诊者98例，均接受FOLFIRI方案一线化疗，化疗前检测肿瘤组织TOPO-1的表达水平，分析TOPO-1表达水平与近期疗效的关系，并观察远期疗效。结果 TOPO-1 表达水平与转移性结直肠癌的临床特征无明显相关性（P＞0.05）。高表达组患者RR为52.2%（24/46），低表达组RR为28.8%（15/52），差异有统计学意义（P<0.05）。TOPO-1高表达组中位PFS为9.5个月（8~12个月），低表达组为8.0个月（7~9个月），差异有统计学意义（P=0.002）。结论 TOPO-1高表达转移性结直肠癌患者可从伊立替康化疗中获得更高的近期疗效和更长的无疾病进展生存时间，可能对伊立替康化疗更敏感。

Correlation of TOPO-1 expression with irinotecan therapy in patients with metastatic colorectal cancer

Objective To explore TOPO-1 expression in patients with metastatic colorectal cancer. Methods TOPO-1 expression was detected by immunohistochemistry in 98 cases of metastatic colorectal cancer before receiving FOLFIRI chemotherapy，and investigate its association with short-term efficacy of chemotherapy.The long-term efficacy of chemotherapy was evaluated. Results TOPO-1 expression showed no obvious correlation with clinico-pathological characteristics（P＞0.05）. The patients showing high and low TOPO-1 expression showed significant difference between response rate（52.2% vs 28.8%，P＜0.05）and median progression-free survival（9.5 months vs 8.0 months，P=0.002）.  Conclusion Irinotecan showed a tendency toward higher response rate and longer median survival for treating metastatic colorectal cancer patients with high expression of TOPO-1.